Nanobiotix (NBTX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NBTX Nanobiotix

Watchlist

3.350
-0.120-3.46%

Close Nov 27 16:00 ET

158.81MMarket Cap-4317P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Nanobiotix Strengthens Growth and Financial Prospects
TipRanksNov 12 10:43 ET
Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves
BenzingaNov 12 02:58 ET
Press Release: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
Dow JonesNov 12 02:30 ET
NANOBIOTIX to Participate in Multiple Investor Conferences in November
GlobeNewswireOct 31 03:30 ET
Nanobiotix Updates Voting Rights and Capital Shares
TipRanksOct 11 16:47 ET
Express News | Nanobiotix SA : Jefferies Cuts Target Price to $10.6 From $11
ReutersSep 23 01:16 ET

Comments

Jaguar8

Jun 12 15:17

NEWS

$Nanobiotix (NBTX.US)$
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, whe...

Jaguar8

Jun 2 10:37

NEWS

$Nanobiotix (NBTX.US)$
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announced new data from Study 1100, showing disease control and tumor response in patients treated with RT-activated NBTXR3 followed by anti-PD-1 therapy for second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The stud...

Jaguar8

May 28 15:16

NEWS

$Nanobiotix (NBTX.US)$
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) has announced the presentation of new data from its US Phase 1 Study 1100 at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO). The study evaluates NBTXR3 combined with anti-PD-1 therapy in patients with recurre...

Jaguar8

May 21 15:21

$Nanobiotix (NBTX.US)$
NEWS
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix has announced significant progress in its global collaboration with Janssen to develop and commercialize its radioenhancer NBTXR3. This collaboration aims to expand the application of NBTXR3 in treating cancer patients who undergo radiotherapy. Key updates include the removal of a planned futility analysis for the ongoing Phas...

Rivera

Aug 7, 2023 07:05

$Nanobiotix (NBTX.US)$

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

NBTX Nanobiotix

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target